Alnylam Pharmaceuticals (ALNY) Assets Average (2010 - 2026)

Alnylam Pharmaceuticals has reported Assets Average for 17 years, with the latest figure at $5.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 19.42% year-over-year to $5.0 billion; the trailing twelve-month figure through Mar 2026 stood at $5.0 billion (up 19.42% YoY), and the FY2025 full-year result was $4.6 billion, up 14.08% from the prior year.
• Assets Average for Q1 2026 stood at $5.0 billion, up from $4.9 billion in the prior quarter.
• The five-year high for Assets Average was $5.0 billion in Q1 2026, with the low at $3.4 billion in Q2 2022.
• Historically, Assets Average has averaged $4.0 billion across 5 years, with a median of $3.8 billion in 2023.
• Annual changes were most pronounced in 2023 — Assets Average dropped 1.96% — and 2026, when it advanced 19.42%.
• Alnylam Pharmaceuticals' Assets Average stood at $3.5 billion in 2022, then climbed by 8.29% to $3.8 billion in 2023, then increased by 10.12% to $4.2 billion in 2024, then grew by 16.26% to $4.9 billion in 2025, then increased by 2.83% to $5.0 billion in 2026.
• The last three Assets Average figures came in at $5.0 billion (Q1 2026), $4.9 billion (Q4 2025), and $4.7 billion (Q3 2025), per Business Quant data.